Calysta, a San Mateo CA-based biotechnology company focused on alternative protein producer, raised $39M in Series D-1 funding.
The round was led by bp ventures with participation from were Adisseo, AquaSpark and WTI, as well as other existing investors.
The company intends to use the funds to support global scale-up of production of its FeedKind protein. The round will support scoping and pre development of Calysta’s site, outside Asia.
Led by Thomas Huot, Ph.D. and COO, Calysta provides new food products with high value nutritional ingredients that don’t interfere with the human food chain. The company develops and commercializes FeedKind® protein, a sustainable, traceable alternative feed ingredient for fish, livestock and pet nutritional products. The technology produces sustainable single-cell protein, which is produced through a proprietary, commercially validated gas fermentation process using naturally occurring, non-GM microbes that use methane as their energy source.
Calysta is currently working towards completion of a commercial FeedKind production facility in China via Calysseo, its 50/50 joint venture with Adisseo. It is set to come online late 2022.
The company also operates an R&D facility in the UK.